DISC MEDICINE INC. -

Disc Medicine to Participate in the Jefferies Healthcare Conference

31 May 2023 16:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

11 May 2023 10:15:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

21 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

13 Apr 2023 11:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

31 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

21 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

16 Feb 2023 08:00:56 By Nasdaq GlobeNewswire

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

14 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in SVB Securities Global Biopharma Conference

08 Feb 2023 16:00:00 By Nasdaq GlobeNewswire